Find trials
Search tips

A Study to Evaluate the Use of Lung and intra-abdominal vessels Ultrasond for Intradialytic Complications in Hospitalized Patients on Intermittent Hemodialysis

Overview

About this study

The purpose of this study is to investigate hospitalized, non-ICU patients undergoing intermittent hemodialysis (HD) to determine:

  • If the combined use of lung and intra-abdominal vessels ultrasound in volume assessment would be better for estimation of dry weight
  • If the changes of the lung ultrasound B line numbers as well as portal venous flow pulsatility and IVC diameters could predict intra-dialytic manifestations and/or complications, such as hypotension, hypertension, tachycardia, and change in oxygen requirements
  • If findings seen with a hand-held scanner are similar to a portable ultrasound scanner

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients on intermittent hemodialysis (HD) while hospitalized at Saint Mary’s Hospital.

  • Non-ICU patients are included if they are:

    • At least 18 years old;
    • Currently inpatient at St. Mary’s hospital for any reason;
    • Requiring HD during the hospitalization; and
    • Agreeing to provide informed verbal consent for ultrasound scans before and after HD.

Exclusion Criteria:

  • Known pregnancy at study entry or during the study period.
  • Non-functional arteriovenous fistula in the contralateral arm of the one used as vascular access for the HD session that could interfere with ambulatory blood pressure monitoring.
  • Active malignant disease or other advanced non-cardiac comorbid condition resulting in poor prognosis.
  • History of drug or alcohol abuse or known severe mental disorder.
  • Hemoglobin less than 7 g/dl.
  • Cardiac arrhythmia.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

James Gregoire, M.D.

Contact us for the latest status

Contact information:

James Gregoire M.D.

(507) 284-2944

jgregoire@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20489395

Mayo Clinic Footer